Orthofix Investor Presentation Deck

Orthofix Q1 2023 Highlights *Constant Currency is calculated by applying foreign currency rates applicable to the comparable, prior-year period to present the current period net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates. **The reasons for and nature of non-GAAP disclosures by the Company, descriptions of the adjustments used to calculate those non-GAAP financial measures, and reconciliations of those non-GAAP financial measures to the most comparable GAAP financial measure, are provided in the Company's press release issued and Current Report on Form 8-K filed on May 9, 2023. Total Revenue $175.2M 66% Growth YoY at Constant Currency* 12% Pro-forma Growth YoY at Constant Currency** $47.7M BGT 14% Growth YoY ©2023 Orthofix Medical Inc. All rights reserved | 14 Orthopedics Revenue $26.0M $50.0M Cash & Cash Equivalents, 3/31/2023 $51M of current borrowings under credit facility Global Orthopedics Revenue 14% Growth YoY at Constant Currency* Global Spine Revenue $60.9M $40.6M Biologics Spinal Implants & Enabling Technology 13% Pro-forma Growth YoY at Constant Currency** 7% Pro-forma Growth YoY at Constant Currency** $3.2M 71% Adj. EBITDA** Adj. Gross Margin** ORTHOFIX® SeaSpine

View entire presentation